-

06:23:36 PM

CLNN Stock News

CLNN - Clene Inc

01/11/23 8:00 AM

Nasdaq : CLNN

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications

RHEA-AI

neutral

12/27/22 4:01 PM

Nasdaq : CLNN

clinical trialcovid-19

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and

RHEA-AI

neutral

12/12/22 8:00 AM

Nasdaq : CLNN

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a

RHEA-AI

very positive

11/28/22 8:00 AM

Nasdaq : CLNN

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No approved MS DMTs have shown

RHEA-AI

neutral

11/07/22 8:00 AM

Nasdaq : CLNN

earnings

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

Secondary survival endpoint for the CNM-Au8 ® 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted ventilation) and risk of death alone at 24 weeks. This survival benefit was consistent with prior

RHEA-AI

neutral

10/31/22 8:00 AM

Nasdaq : CLNN

offering

Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today

RHEA-AI

neutral

10/03/22 8:00 AM

Nasdaq : CLNN

clinical trial

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24

RHEA-AI

positive

09/30/22 4:12 PM

Nasdaq : CLNN

conferencesclinical trial

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the

RHEA-AI

neutral

09/21/22 7:00 AM

Nasdaq : CLNN

Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization Comparable survival benefits were also shown compared to ENCALS predicted median survival C NM-Au8 treatment was well-tolerated, and there were no

RHEA-AI

positive

08/30/22 7:00 AM

Nasdaq : CLNN

conferences

Clene to Present at Upcoming September Investor Conferences

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today

RHEA-AI

neutral

1 2 3 4 5 6 7 Next